Document is current
Any future updates will be listed below
-
Authors
Fong, Warren https://orcid.org/0000-0003-1891-1892
Woon, Ting Hui
Chew, Li-Ching
Low, Andrea
Law, Annie
Poh, Yih Jia
Yeo, Siaw Ing
Leung, Ying Ying
Ma, Margaret
Santosa, Amelia
Kong, Kok Ooi
Xu, Chuanhui
Teng, Gim Gee
Mak, Anselm
Tay, Sen Hee
Chuah, Tyng Yu
Roslan, Nur Emillia
Angkodjojo, Stanley
Phang, Kee Fong
Sriranganathan, Melonie
Tan, Teck Choon
Cheung, Peter
Lahiri, Manjari
- License Information
-
More Information
Article History
Received: 1 December 2022
Accepted: 19 July 2023
First Online: 1 August 2023
Declarations
:
: This study was approved by National Health Group Domain Specific Review Board (Reference number: 2021/00433). Waiver of consent was approved for this study.
: Not applicable.
: WF: Speakers bureau: Abbvie, DKSH, GSK and Novartis; THW: None declared; LCC: Speakers bureau: Pfizer and Abbvie, Consultant of: Pfizer and Abbvie Advisory Board meetings, Grant/research support: Abbvie educational grant; ALow: Speakers bureau: Boehringer Ingeilheim, Consultant of: Boehringer Ingeilheim and J&J consultant/ steering group committee; ALaw: None declared; YJP: None declared; SIY: Grant/research support: Multiple pharmaceutical companies for the support of the National Biologics Registry; YYL: Speakers bureau: Abbvie, DKSH, Jassen, Novartis and Pfizer; MM: Grant/research support: Multiple pharmaceutical companies for the support of the National Biologics Registry; AS: Speakers bureau: Amgen Talk, Consultant of: Pfizer ad board; KOK: None declared; CX: None declared; GGT: Speakers bureau: Boehringer Ingleheim; AM: Speakers bureau: J&J and GSK, Grant/research support: GSK—the supported studies programme; SHT: None declared; TYC: None declared; NER: None declared; SA: Speakers bureau: Boehringer Ingeilheim, Consultant of: Abbvie and DKSH; KFP: None declared; MS: None declared; TCT: None declared; PC: Consultant of: Boehringer Ingleheim ad board, Novartis, Janssen and Abbvie, Grant/research support: Novartis; ML: Speakers bureau: J&J and DKSH, Consultant of: DKSH and Gilead, Grant/research support: Multiple pharmaceutical companies for the support of the National Biologics Registry.
